Chimeric antigen receptor (CAR) T cell therapies are being investigated to provide patients with hematologic cancers an alternative treatment using the immune system. These biological products are unique in that they are produced by adding chimeric antigen receptors (CARs) to a patient’s T cells; the CAR can recognize and attack cells that display particular protein (antigen), including cancer cells.
The author will present a high level summary of CAR T cell therapy, basic considerations during process development and process validation activities.
Dr. Humberto Vega, Sr. Director of Celgene, S12 CAR T Manufacturing Science & Technology, Summit, NJ
Bring a non-member guest and receive a $25 gift card!
Silver Sponsor - $250
One free registration, recognition on announcements, at the event, in newsletter
Gold Sponsor - $500
Two free registrations, recognition on announcements, at the event, in newsletter
Sponsor early for the maximum exposure!
Feel free to forward this to your colleagues